Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Not yet recruiting 3Active not recruiting 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Locally Recurrent Skin Squamous Cell Carcinoma 1

Interventions

Specimen Handling 28Magnetic Resonance Spectroscopy 19Biopsy 18Cyclophosphamide 7venetoclax 5Vincristine 5Bevacizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Radiosurgery 3Radiation 3Prednisone 3Injections 3Doxorubicin 3Cetuximab 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2fludarabine 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hyaluronoglucosaminidase × 90 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡